Skip to main content
. Author manuscript; available in PMC: 2019 Jan 20.
Published in final edited form as: J Proteome Res. 2017 Aug 8;16(9):3266–3276. doi: 10.1021/acs.jproteome.7b00245

Table 2.

Patient Characteristics for IHC Validation Cohort

patients no cancer(%) cancer(%) P value

N = 63 N = 86
age ± SD 66.3 ± 20.9 62.9 ± 10.4 0.616a
gender 0.381b
   male 31 (49) 49 (57)
   female 32 (51) 37 (43)
race 0.179b
   Caucasian 58 (92) 84 (98)
   African American 3 (5) 2 (2)
   other 2 (3) 0 (0)
nodule size (mm) ± SD 22.0 ± 16.0 30.0 ± 20.0 0.014a
smoking status <0.001b
   never smoker 20 (32) 6 (7)
   ex-smoker 33 (53) 55 (63)
   current smoker 10 (16) 25 (29)
pack years ± SD 27.0 ± 30.1 45.5 ± 31.7 <0.001a
FEV1% ± SD 67.0 ± 22.5 65.3 ± 24.1 0.660a
lung cancer histologies
   ADC 41 (48)
   SCC 31 (36)
   NSCLC 7 (8)
   LCC 5 (6)
   carcinoid 2 (2)
path stages
   IA-IB 55 (64)
   IIA-IIIA 19 (22)
   IIIB-IV 12 (14)
benign histologies
   acid fast bacilli 5 (8)
   acute inflam. 3 (5)
   benign tumor 2 (2)
   fungal 25 (40)
   multiple etiologies 25 (40)
   normal lung 3 (5)
a

Wilcoxon Rank Sum Test.

b

Pearson Chi-Square Test.